ES2217274T3 - Antagonistas de receptor nk-1 para el tratamiento de lesiones neuronales y accidentes cerebrovasculares. - Google Patents
Antagonistas de receptor nk-1 para el tratamiento de lesiones neuronales y accidentes cerebrovasculares.Info
- Publication number
- ES2217274T3 ES2217274T3 ES95308876T ES95308876T ES2217274T3 ES 2217274 T3 ES2217274 T3 ES 2217274T3 ES 95308876 T ES95308876 T ES 95308876T ES 95308876 T ES95308876 T ES 95308876T ES 2217274 T3 ES2217274 T3 ES 2217274T3
- Authority
- ES
- Spain
- Prior art keywords
- derivatives
- stroke
- treatment
- epilepsy
- mammals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
LA PRESENTE INVENCION SE REFIERE A UN METODO PARA EL TRATAMIENTO O PREVENCION DE UNA ENFERMEDAD SELECCIONADA ENTRE LOS ATAQUES, LA EPILEPSIA, LOS TRAUMATISMOS CRANEALES, LOS TRAUMATISMOS DE LA MEDULA ESPINAL, EL DAÑO NEURONAL ISQUEMICO COMO EL DAÑO ISQUEMICO CEREBRAL, PRODUCIDO POR UN ATAQUE U OCLUSION VASCULAR (P.EJ. DURANTE LA CIRUGIA A CORAZON ABIERTO), EL DAÑO NEURONAL EXCITOTOXICO (P.EJ. LOS ATAQUES O LA EPILEPSIA) Y LA ESCLEROSIS LATERAL AMIOTROFICA EN LOS MAMIFEROS, INCLUIDOS LOS HUMANOS, QUE EMPLEA UN ANTAGONISTA NK-1. TAMBIEN SE REFIERE A UN METODO PARA EL TRATAMIENTO O PREVENCION DE DICHAS ENFERMEDADES EN LOS MAMIFEROS, INCLUIDOS LOS HUMANOS, UTILIZANDO CIERTOS DERIVADOS DE LA QUINUCLIDINA, DERIVADOS DE PIPERIDINA, DERIVADOS DE PIRROLIDINA, DERIVADOS DE AZANORBORNANO, DERIVADOS DE LA ETILENDIAMINA Y LOS COMPUESTOS RELACIONADOS QUE SON ANTAGONISTAS DEL RECEPTOR DE LA SUBSTANCIA P.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35470294A | 1994-12-12 | 1994-12-12 | |
US354702 | 1994-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2217274T3 true ES2217274T3 (es) | 2004-11-01 |
Family
ID=23394558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95308876T Expired - Lifetime ES2217274T3 (es) | 1994-12-12 | 1995-12-07 | Antagonistas de receptor nk-1 para el tratamiento de lesiones neuronales y accidentes cerebrovasculares. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6376507B1 (es) |
EP (1) | EP0721778B1 (es) |
JP (1) | JPH08239323A (es) |
KR (1) | KR100195651B1 (es) |
CN (1) | CN1132072A (es) |
AT (1) | ATE260656T1 (es) |
AU (1) | AU719159B2 (es) |
CA (1) | CA2164804C (es) |
DE (1) | DE69532625T2 (es) |
DK (1) | DK0721778T3 (es) |
ES (1) | ES2217274T3 (es) |
IL (1) | IL116249A (es) |
MY (1) | MY138631A (es) |
NZ (1) | NZ280627A (es) |
PT (1) | PT721778E (es) |
ZA (1) | ZA9510483B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
CO5011067A1 (es) * | 1997-11-03 | 2001-02-28 | Novartis Ag | Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen |
AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
MXPA06013677A (es) * | 2004-05-25 | 2007-02-13 | Pfizer Prod Inc | Derivados de 3-amino-2-fenilpirrolidina. |
GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
JP6334098B2 (ja) * | 2013-06-24 | 2018-05-30 | セイコーインスツル株式会社 | 表示機構、時計用ムーブメントおよび時計 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
ATE113947T1 (de) * | 1990-06-01 | 1994-11-15 | Pfizer | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. |
DE69106365T2 (de) * | 1990-07-23 | 1995-05-04 | Pfizer | Chinuclidinderivate. |
WO1992012151A1 (en) * | 1991-01-10 | 1992-07-23 | Pfizer Inc. | N-alkyl quinuclidinium salts as substance p antagonists |
ATE115581T1 (de) * | 1991-03-01 | 1994-12-15 | Pfizer | 1-azabicyclo(3.2.2>nonan-3-aminderivate. |
KR100214905B1 (ko) * | 1991-05-31 | 1999-08-02 | 디. 제이. 우드, 스피겔 알렌 제이 | 퀴누클리딘 유도체 |
CA2118704C (en) * | 1991-09-26 | 1997-01-21 | John A. Lowe, Iii | Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists |
JP2656702B2 (ja) * | 1992-03-23 | 1997-09-24 | ファイザー製薬株式会社 | ペプチド性キヌクリジン |
DK0655996T3 (da) * | 1992-08-19 | 2001-12-27 | Pfizer | Substituerede benzylamino-nitrogenholdige, ikke-aromatiske, heterocykliske forbindelser |
WO1995007908A1 (en) * | 1993-09-17 | 1995-03-23 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
EP0712778B1 (fr) * | 1994-11-16 | 1999-04-21 | Bird Sa | Cadre de cycle modulable et caractéristiques anti-vibratoires d'un tel cadre |
IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
-
1995
- 1995-12-04 IL IL11624995A patent/IL116249A/xx not_active IP Right Cessation
- 1995-12-05 MY MYPI95003742A patent/MY138631A/en unknown
- 1995-12-07 DE DE69532625T patent/DE69532625T2/de not_active Revoked
- 1995-12-07 DK DK95308876T patent/DK0721778T3/da active
- 1995-12-07 EP EP95308876A patent/EP0721778B1/en not_active Revoked
- 1995-12-07 ES ES95308876T patent/ES2217274T3/es not_active Expired - Lifetime
- 1995-12-07 AT AT95308876T patent/ATE260656T1/de not_active IP Right Cessation
- 1995-12-07 PT PT95308876T patent/PT721778E/pt unknown
- 1995-12-08 NZ NZ280627A patent/NZ280627A/en unknown
- 1995-12-08 CN CN95120596A patent/CN1132072A/zh active Pending
- 1995-12-08 CA CA002164804A patent/CA2164804C/en not_active Expired - Fee Related
- 1995-12-08 AU AU40304/95A patent/AU719159B2/en not_active Ceased
- 1995-12-09 KR KR1019950048062A patent/KR100195651B1/ko not_active IP Right Cessation
- 1995-12-11 ZA ZA9510483A patent/ZA9510483B/xx unknown
- 1995-12-12 JP JP7323355A patent/JPH08239323A/ja active Pending
-
1998
- 1998-06-18 US US09/099,289 patent/US6376507B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR100195651B1 (ko) | 1999-06-15 |
MY138631A (en) | 2009-07-31 |
AU719159B2 (en) | 2000-05-04 |
EP0721778A2 (en) | 1996-07-17 |
US6376507B1 (en) | 2002-04-23 |
EP0721778A3 (en) | 1999-11-10 |
CA2164804A1 (en) | 1996-06-13 |
IL116249A0 (en) | 1996-03-31 |
ATE260656T1 (de) | 2004-03-15 |
NZ280627A (en) | 2000-06-23 |
DE69532625D1 (de) | 2004-04-08 |
PT721778E (pt) | 2004-07-30 |
DK0721778T3 (da) | 2004-07-12 |
JPH08239323A (ja) | 1996-09-17 |
CN1132072A (zh) | 1996-10-02 |
AU4030495A (en) | 1996-06-20 |
EP0721778B1 (en) | 2004-03-03 |
CA2164804C (en) | 1999-07-27 |
KR960021025A (ko) | 1996-07-18 |
DE69532625T2 (de) | 2005-02-03 |
IL116249A (en) | 2003-07-06 |
ZA9510483B (en) | 1997-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0686629A3 (en) | Cyclohexyl tachykinine receptor antagonists | |
PL369535A1 (en) | Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
BR9609019A (pt) | Compostos ativos em um novo local sobre canais de cálcio operados por receptor úteis no tratamento de desordens e doenças neurológicas | |
IL146871A0 (en) | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | |
ZA200306493B (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists. | |
HUP9901629A2 (hu) | R(+)-N-Propargil-1-amino-indán és sói, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
EP0722737A4 (en) | REMEDY AGAINST AFFECTS OF CRANIAL NERVES | |
ZA90944B (en) | Compounds which are antagonists of excitatory amino acid receptors | |
WO2007098283A3 (en) | Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders | |
WO2006017673A3 (en) | Taj in neuronal function | |
ES2217274T3 (es) | Antagonistas de receptor nk-1 para el tratamiento de lesiones neuronales y accidentes cerebrovasculares. | |
EP0703785A4 (en) | METHODS FOR TREATING MUSCLE DISEASES AND MUSCLE DISORDER | |
ZA200203701B (en) | Polycycloalkylpurines as adenosine receptor antagonists. | |
CY1106560T1 (el) | Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων | |
DE60140054D1 (de) | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen | |
AU4089889A (en) | Method of treating skin injuries using thromboxane a2 receptor antagonists | |
IL111579A0 (en) | Melatonin derivatives for use in treating desynchronization disorders | |
WO2002099069A3 (en) | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule | |
MX9703483A (es) | Antagonistas del receptor de nk-1 para el tratamiento de trastornos oculares. | |
ATE161856T1 (de) | Verfahren zum thermomechanischen abbau von polyolefinen | |
DE69800906T2 (de) | Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie | |
MX9709911A (es) | Compuestos activos en un sitio novedoso en canales de calcio operados por receptor utiles para el tratamiento de trastornos neurologicos. | |
ZA971323B (en) | Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl-amino)piperidin 1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases. | |
IT1296424B1 (it) | Dispositivo per la prevenzione e la cura di disturbi causati da lavoro o da permanenza prolungata davanti ad apparecchi video, come | |
RU93035807A (ru) | Способ лечения юношеского эпифизиолиса |